Verition Fund Management
INZY

Verition Fund Management’s Inozyme Pharma INZY Stock Holding History

Verition Fund Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,900
Closed -$137K – 2375
2023
Q1 		$137K Buy
+23,900
New +$63.2K ﹤0.01% 1863

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Verition Fund Management's INZY Position: Q2 2023 in Review

Verition Fund Management sold out of Inozyme Pharma (INZY) in Q2 2023, closing a stake of 23,900 shares — an estimated $137K sold.

Verition Fund Management first reported a position in INZY in Q1 2023 and held it in 1 quarter. The position peaked at $137K in Q1 2023. 74 funds tracked by Wall St. Rank hold INZY as of Q2 2023.

  • Verition Fund Management reported no remaining Inozyme Pharma position as of Q2 2023 after selling out during the quarter.
  • Verition Fund Management sold 23,900 Inozyme Pharma shares in Q2 2023, an estimated $137K.
  • Verition Fund Management first reported a position in Inozyme Pharma in Q1 2023 and held it in 1 quarter.
  • Verition Fund Management's Inozyme Pharma position peaked at $137K in Q1 2023.
  • 74 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2023.

Based on Verition Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.